PureTech Health plc (PRTC) is a Biotechnology company in the Healthcare sector, currently trading at $17.87. It has a SharesGrow Score of 72/100, indicating a above average investment profile with 4 out of 7 criteria passed.
Analyst consensus target is PRTC = $57 (+219% upside).
Valuation: PRTC trades at a trailing Price-to-Earnings (P/E) of 7.5 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 1.05.
Financials: revenue is $4M, +3.3%/yr average growth. Net income is $54M, growing at +48.4%/yr. Net profit margin is 1240.1% (strong). Gross margin is 100% (+1107 pp trend).
Balance sheet: total debt is $22M against $415M equity (Debt-to-Equity (D/E) ratio 0.05, conservative). Current ratio is 9.33 (strong liquidity). Debt-to-assets is 3.7%. Total assets: $603M.
Analyst outlook: 2 / 2 analysts rate PRTC as buy (100%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 91/100 (Pass), Growth 73/100 (Pass), Past 25/100 (Fail), Health 67/100 (Partial), Moat 50/100 (Partial), Future 100/100 (Pass), Income 100/100 (Pass).
